Further, the PBRM1 mutations can also help predict response and prognosis to VEGF inhibitors: RCC patients treated on the COMPARZ trial harboring PBRM1 mutations correlated with better overall survival (OS), progression free survival (PFS), objective response rate and enhanced the angiogenic microenvironment [11]. Here, PBRM1 is linked to renal cell carcinoma.